孤立性生长激素缺乏症和特发性身材矮小：生长激素治疗至成人身高后的比较疗效
Isolated Growth Hormone Deficiency and Idiopathic Short Stature: Comparative Efficiency after Growth Hormone Treatment up to Adult Height.
作者信息
Ariza-Jimenez Ana-Belen, Leiva Gea Isabel, Martinez-Aedo Ollero Maria Jose, Lopez-Siguero Juan Pedro
机构信息
Pediatric Endocrinology, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain.
Pediatric Research, Fundación Pública Andaluza Para la Investigación de Málaga en Biomedicina y Salud, 29010 Málaga, Spain.
出版信息
J Clin Med. 2021 Oct 27;10(21):4988. doi: 10.3390/jcm10214988.
INTRODUCTION
Treatment with growth hormone (GH) is not approved for idiopathic short stature (ISS) in Europe.
OBJECTIVES
To compare the growth of children treated with isolated GH deficiency (IGHD) vs. ISS-treated and untreated children.
METHODS
A retrospective descriptive study of patients treated in the last 14 years for IGHD (Group A), in comparison with ISS-treated (Group B) and untreated (Group C) subjects.
RESULTS
Group A had 67 males, who showed a height gain of 1.24 SD. Group B had 30 boys, who showed a height gain of 1.47 SD. Group C had 42 boys, who showed an improvement of 0.37 SD. The final heights were -1.52 SD, -1.31 SD, and -2.03 SD, respectively. Group A and C did not reach their target heights (with differences of 0.27 SD and 0.59 SD, respectively). Group B surpassed their target height by 0.29 SD.
CONCLUSIONS
The final heights of the IGHD and treated ISS are similar. Treated groups were taller than untreated groups.
引言
在欧洲，生长激素（GH）治疗特发性矮小症（ISS）未获批准。
目的
比较孤立性生长激素缺乏症（IGHD）患儿与接受生长激素治疗和未接受治疗的ISS患儿的生长情况。
方法
一项回顾性描述性研究，对过去14年中接受IGHD治疗的患者（A组）与接受生长激素治疗的ISS患者（B组）和未接受治疗的ISS患者（C组）进行比较。
结果
A组有67名男性，身高增长了1.24标准差。B组有30名男孩，身高增长了1.47标准差。C组有42名男孩，身高改善了0.37标准差。最终身高分别为-1.52标准差、-1.31标准差和-2.03标准差。A组和C组未达到其目标身高（分别相差0.27标准差和0.59标准差）。B组超过其目标身高0.29标准差。
结论
IGHD和接受生长激素治疗的ISS患者的最终身高相似。接受治疗的组比未接受治疗的组更高。
Zotero 插件